On July 15th, the Center for Tobacco Products (CTP) of the US Food and Drug Administration (FDA) published two notices in the Federal Register, stating their plans to launch a new generation CTP web portal next year for the submission of certain new tobacco product applications.
The purpose of this improvement is:
Integration of major Substantial Equivalence (SE) reports and Premarket Tobacco Product Applications (PMTAs), previously submitted amendments, and general correspondence into one system; introducing a more efficient submission process by eliminating the need for multiple tools (including consolidating PDF editing software, FDA's eSubmitter desktop tool, and FDA's CTP Portal web application into one place); providing tools to expedite data entry, guide applicants to relevant sections, and verify that all necessary data has been provided. No action is required for current users of any CTP system for these improvements in the works. Existing CTP Portal accounts and any pending or ongoing applications will automatically migrate to the new CTP Portal Next Generation. CTP will provide additional communication and support before the changes take effect.
As part of submitting SE reports and PMTAs in the CTP Portal Next Generation, applicants will need to enter certain information on the applicable forms. Therefore, two Federal Register notices (one regarding SE, one regarding PMTA) announced today are seeking public input on entering this information.
The public comment period will begin on July 16 and end on September 14 at 11:59 PM (Eastern Time).
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
![[2Firsts Special Report] EPO Enlarged Board of Appeal Issues Key Decision: China YTI Gains Procedural Advantage in Heated Tobacco Patent Dispute with Philip Morris](https://static.2firsts.com/uploads/20250619/680a1f4818d125725c6608db46873b7a.png?x-oss-process=style/origin)
